Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaGünter U. Höglinger, Keith A. Josephs, Anthony E. Lang et al.|Movement Disorders|2017Cited by 2.3k
Which ante mortem clinical features predict progressive supranuclear palsy pathology?Gesine Respondek, Carolin Kurz, Thomas Arzberger et al.|Movement Disorders|2017Cited by 163
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Karl Kieburtz, Shane Rosanbalm et al.|The Lancet Neurology|2023Cited by 128